1169792
Last Update Posted: 2010-07-26
Recruiting has ended
All Genders accepted | 18 Years + |
Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen.
The investigators want to
- evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and
- analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.
Eligibility
Relevant conditions:
Breast Neoplasms
Survival Analysis
Antineoplastic Agents
Therapeutic Uses
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov